March 10, 2020 / 12:29 PM / 22 days ago

BRIEF-Mylan Pharmaceuticals Launches Wixela Inhub In Canada

March 10 (Reuters) - Mylan NV:

* MYLAN PHARMACEUTICALS ULC LAUNCHES WIXELA® INHUB® (FLUTICASONE PROPIONATE AND SALMETEROL INHALATION POWDER, USP), THE FIRST AVAILABLE BIOEQUIVALENT ALTERNATIVE TO ADVAIR® DISKUS® (FLUTICASONE PROPIONATE AND SALMETEROL INHALATION POWDER) IN CANADA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below